Jeff Yass’s Oramed Pharmaceuticals ORMP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$78.9K Buy
+16,900
New +$76.4K ﹤0.01% 12689
2025
Q3
– Sell
-23,400
Closed -$52.6K – 13487
2025
Q2
$52.6K Buy
+23,400
New +$51.6K ﹤0.01% 12094
2024
Q1
– Sell
-19,700
Closed -$45.5K – 13015
2023
Q4
$45.5K Buy
+19,700
New +$42.1K ﹤0.01% 11747
2023
Q1
– Sell
-112,500
Closed -$1.35M – 13220
2022
Q4
$1.35M Buy
112,500
+92,100
+451% +$716K ﹤0.01% 5509
2022
Q3
$132K Sell
20,400
-17,600
-46% -$142K ﹤0.01% 11408
2022
Q2
$174K Sell
38,000
-31,700
-45% -$169K ﹤0.01% 10842
2022
Q1
$603K Buy
69,700
+2,500
+4% +$25.6K ﹤0.01% 8477
2021
Q4
$960K Sell
67,200
-108,100
-62% -$2.26M ﹤0.01% 7407
2021
Q3
$3.85M Buy
175,300
+98,000
+127% +$1.67M ﹤0.01% 4430
2021
Q2
$1.03M Buy
77,300
+9,400
+14% +$108K ﹤0.01% 7674
2021
Q1
$690K Buy
67,900
+38,500
+131% +$316K ﹤0.01% 8701
2020
Q4
$125K Buy
29,400
+6,000
+26% +$19.5K ﹤0.01% 10371
2020
Q3
$61K Sell
23,400
-24,400
-51% -$85K ﹤0.01% 10147
2020
Q2
$169K Sell
47,800
-6,500
-12% -$21.8K ﹤0.01% 9175
2020
Q1
$165K Buy
54,300
+7,600
+16% +$33.3K ﹤0.01% 8902
2019
Q4
$241K Buy
+46,700
New +$175K ﹤0.01% 8424
2016
Q4
– Sell
-73,400
Closed -$533K – 9970
2016
Q3
$533K Sell
73,400
-35,300
-32% -$274K ﹤0.01% 5954
2016
Q2
$907K Buy
108,700
+69,000
+174% +$588K ﹤0.01% 5057
2016
Q1
$264K Sell
39,700
-1,100
-3% -$7.36K ﹤0.01% 7469
2015
Q4
$349K Buy
40,800
+17,100
+72% +$130K ﹤0.01% 7421
2015
Q3
$130K Sell
23,700
-9,300
-28% -$58.5K ﹤0.01% 9011
2015
Q2
$187K Buy
+33,000
New +$226K ﹤0.01% 9335
2015
Q1
– Sell
-11,000
Closed -$50K – 9784
2014
Q4
$50K Buy
+11,000
New +$72.3K ﹤0.01% 9365
2014
Q3
– Sell
-12,200
Closed -$117K – 9791
2014
Q2
$117K Buy
+12,200
New +$125K ﹤0.01% 9369

Other funds holding ORMP

Jeff Yass's ORMP Position: Q3 2026 in Review

Jeff Yass sold out of Oramed Pharmaceuticals (ORMP) in Q3 2026, closing a stake of 22,300 shares — an estimated $101K sold.

Jeff Yass first reported a position in ORMP in Q1 2014 and held it in 31 quarters. The position peaked at $2.23M in Q4 2022. 87 funds tracked by Wall St. Rank hold ORMP as of Q3 2026.

  • Jeff Yass reported no remaining Oramed Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Jeff Yass sold 22,300 Oramed Pharmaceuticals shares in Q3 2026, an estimated $101K.
  • Jeff Yass first reported a position in Oramed Pharmaceuticals in Q1 2014 and held it in 31 quarters.
  • Jeff Yass's Oramed Pharmaceuticals position peaked at $2.23M in Q4 2022.
  • 87 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.